Study	Treatment (Events/Total)	Control (Events/Total)		Shrinkage OR [95% CrI]	Observed OR [95% CI]
Abd Ellatif 2024	1/40	7/40		0.34 [0.10, 0.68]	0.12 [0.01, 1.03]
Chen 2021	7/80	14/80		0.45 [0.20, 0.79]	0.45 [0.17, 1.19]
Choovongkom ol 2024	18/100	40/100		0.36 [0.18, 0.58]	0.33 [0.17, 0.63]
Deiner 2017	23/189	23/201		0.81 [0.44, 1.33]	1.07 [0.58, 1.98]
Gao 2021	3/20	10/20		0.33 [0.11, 0.66]	0.18 [0.04, 0.80]
Guo 2015	6/78	21/78		0.31 [0.13, 0.56]	0.23 [0.09, 0.60]
He 2021	2/30	3/30		0.48 [0.15, 0.99]	0.64 [0.10, 4.15]
He 2023	3/30	13/30		0.30 [0.10, 0.58]	0.15 [0.04, 0.59]
He 2024	5/40	13/40		0.37 [0.14, 0.69]	0.30 [0.09, 0.93]
Hong 2021	17/356	26/356		0.56 [0.31, 0.90]	0.64 [0.34, 1.19]
Hu 2021	15/90	32/87		0.37 [0.19, 0.62]	0.34 [0.17, 0.70]
Hu 2022	1/20	3/20		0.42 [0.13, 0.90]	0.30 [0.03, 3.15]
Huet 2024	20/166	20/167		0.75 [0.40, 1.27]	1.01 [0.52, 1.95]
Kim 2019	15/73	15/70		0.67 [0.30, 1.18]	0.95 [0.42, 2.12]
Lai 2023	5/30	4/30		0.60 [0.21, 1.23]	1.30 [0.31, 5.40]
Lee 2020	9/107	6/108		0.76 [0.31, 1.48]	1.56 [0.54, 4.55]
Li 2017	7/142	11/143		0.52 [0.22, 0.94]	0.62 [0.23, 1.65]
Li 2020	17/309	32/310		0.49 [0.26, 0.76]	0.51 [0.27, 0.93]
Li 2023	28/130	60/130		0.34 [0.20, 0.53]	0.32 [0.19, 0.55]
Likhvantsev 2021	6/87	16/88		0.39 [0.18, 0.71]	0.33 [0.12, 0.90]
Liu 2016	15/99	43/98		0.28 [0.15, 0.47]	0.23 [0.12, 0.45]
Liu 2021	5/60	8/60		0.50 [0.20, 0.94]	0.59 [0.18, 1.92]
Liu 2023	32/152	36/152		0.72 [0.41, 1.11]	0.86 [0.50, 1.47]
Long 2024	3/39	7/39		0.42 [0.14, 0.83]	0.38 [0.09, 1.60]
Lu 2021	41/404	43/404		0.81 [0.50, 1.18]	0.95 [0.60, 1.49]
Lv 2022	21/163	46/164		0.39 [0.22, 0.61]	0.38 [0.21, 0.67]
Qu 2023	5/188	16/206		0.39 [0.17, 0.70]	0.32 [0.12, 0.90]
Soh 2020	2/54	7/54		0.38 [0.13, 0.75]	0.26 [0.05, 1.31]
Su 2016	32/350	79/350		0.36 [0.23, 0.52]	0.35 [0.22, 0.54]
Tang 2022 - Dexmedetomidine (Dex1, 0.3 mcg/kg/h)	2/40	9/40		0.34 [0.12, 0.67]	0.18 [0.04, 0.90]
Tang 2022 - Dexmedetomidine (Dex2, 0.6 mcg/kg/h)	3/40	9/40		0.38 [0.13, 0.74]	0.28 [0.07, 1.12]
Turan 2020	67/398	46/396		1.25 [0.82, 1.78]	1.54 [1.03, 2.31]
Wang 2023	47/326	51/326		0.79 [0.51, 1.13]	0.91 [0.59, 1.40]
Wu 2023	3/58	7/57		0.43 [0.17, 0.86]	0.39 [0.10, 1.59]
Xin 2021	3/30	10/30		0.35 [0.11, 0.66]	0.22 [0.05, 0.91]
Xing 2021	2/55	8/55		0.37 [0.13, 0.72]	0.22 [0.04, 1.10]
Yang 2015	2/40	5/40		0.42 [0.14, 0.87]	0.37 [0.07, 2.02]
Zhang 2020	20/116	36/116		0.45 [0.25, 0.73]	0.46 [0.25, 0.86]
Zhang 2023	2/58	0/59		0.60 [0.18, 1.37]	5.27 [0.25, 112.09]
van Norden 2021	5/28	14/32		0.36 [0.14, 0.70]	0.28 [0.08, 0.92]
Pooled Effect	**520/4815**	**849/4846**		**0.43 [0.33, 0.53]**	

Favours Dexmedetomidine — Favours Control

Odds Ratio (log scale) 0.1 0.3 1.0 3.0

Data visualization inspired by the bayesfoRest package